Semaglutide for sleep apnea may help when excess weight is part of the cause. But it isn't approved to treat sleep apnea. It doesn't replace a sleep study or prescribed CPAP, a machine that keeps the airway open with steady air pressure.
Obstructive sleep apnea, or OSA, means the airway repeatedly narrows or closes during sleep. Weight can contribute to that blockage. Airway shape and other factors matter too.
Is semaglutide for sleep apnea an approved use?
As of September 30, 2026, the day this article was written, neither the current Wegovy label nor the Ozempic label lists OSA as an indication, or approved treatment use. Their prescribing information reads "Revised: 6/2026" and "Revised: 5/2026," respectively.
A person with obesity and sleep apnea may receive Wegovy for weight management within its labeled use. Prescribing the brand specifically to treat sleep apnea would be off-label, meaning a use outside its prescribing label. Our guide to what off-label use means explains that distinction.
The condition being treated matters. A prescription for weight management isn't evidence that the medicine directly treats overnight breathing problems.
Why weight loss can change overnight breathing
Excess fat around the upper airway can contribute to its narrowing. Semaglutide belongs to the GLP-1 family, medicines that mimic a gut signal involved in appetite and blood sugar. Weight management is the plausible connection to sleep apnea.
Sleep studies report the apnea-hypopnea index, or AHI: breathing pauses or shallow breaths per hour of sleep. The American Academy of Sleep Medicine's severity measure gives these adult ranges:
| Severity | Breathing events per hour |
|---|---|
| Mild | 5 to fewer than 15 |
| Moderate | 15 to fewer than 30 |
| Severe | 30 or more |
The Wisconsin Sleep Cohort followed 690 adults assessed four years apart. A 10% weight loss predicted a 26% decrease in AHI compared with stable weight. Those figures come from Peppard and colleagues in JAMA, 2000.
That study didn't test semaglutide, and its numbers aren't a forecast for one person. Breathing events can decrease while sleep apnea remains. Less snoring isn't the same as a normal sleep study.
What semaglutide studies actually measured
As of September 30, 2026, the day this article was written, semaglutide has encouraging evidence from medical records. A study published January 23, 2026, in Annals of the American Thoracic Society matched 191,273 semaglutide users with 191,273 controls who also had obesity.
New OSA diagnoses were less frequent among semaglutide users. The hazard ratio, a comparison of risk over time, was 0.62. That doesn't count overnight breathing interruptions. Matching made the groups more similar, but it couldn't establish that semaglutide caused the difference.
The researchers also studied people who already had OSA, measuring heart, kidney and survival outcomes. They didn't report how many fewer breathing events those people had during sleep.
A registered semaglutide study of 15 people lists breathing-event change from the start to one week as its main measure, within a four-week follow-up; no results are posted. Its record lists an observational study, meaning treatment wasn't randomly assigned, and has no posted results. It can't yet supply an AHI benefit number.
Published evidence still lacks a dedicated phase 3 semaglutide trial, a large study confirming treatment effects, with AHI results in established OSA. The distinction matters: fewer new diagnoses and improvement of existing sleep apnea are different questions.
Why Zepbound's sleep-apnea indication is different
On December 20, 2024, the FDA added a sleep-apnea indication for Zepbound. It covers moderate-to-severe OSA in adults with obesity, alongside a reduced-calorie diet and increased physical activity.
Zepbound contains tirzepatide, a different medicine from semaglutide. Our guide to tirzepatide for sleep apnea explains the indication. The separate SURMOUNT-OSA results page covers the dedicated breathing trials.
Those results belong to the medicine studied. They don't establish the same breathing benefit for semaglutide. Zepbound's branded indication also doesn't extend to compounded tirzepatide.
Why CPAP still matters after weight loss
CPAP holds the airway open while it is being used. Weight management addresses a contributing factor over time. A sleep clinician may include both in the same plan.
As of September 30, 2026, the day this article was written, a review published September 3, 2026, in JAMA Otolaryngology–Head & Neck Surgery describes GLP-1 medicines as complementary treatment alongside CPAP. It identifies weight loss as their main established connection to improved OSA. The review covers several drugs; its combined findings aren't a semaglutide-specific breathing result.
CPAP remains standard treatment. Weight loss alone doesn't establish that prescribed airway treatment can stop. That decision needs the sleep clinician's reassessment, often including another sleep study.
Tiredness is another imperfect guide. Sleep apnea can cause daytime sleepiness, while medication effects, reduced intake and dehydration can also cause fatigue. Does semaglutide make you tired? explains why the timing and accompanying symptoms matter.
What compounded semaglutide means here
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded means a licensed pharmacy prepares a medication for an individual prescription. The FDA explains that these preparations aren't reviewed for safety, effectiveness or quality before marketing.
A compounded preparation isn't off-label Wegovy or Ozempic. It is a separate product, and findings from branded semaglutide don't establish that a compounded preparation has the same effects.
A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor.
What a provider needs to know
The useful starting information is a sleep-study report, its breathing-event count, and whether prescribed CPAP is being used and tolerated. Weight history, current medicines and pregnancy plans also belong in the review.
The provider needs to know what treatment is meant to address: weight management, diabetes, breathing during sleep, or several concerns together. Those goals can overlap without being interchangeable.
There is no established semaglutide dosage specifically for OSA. The prescriber sets any medication dose and follow-up plan. A sleep clinician remains responsible for reassessing the breathing disorder and any change to airway treatment.
At Promise, a licensed U.S. provider reviews every request and prescribes only when medically appropriate. Not everyone qualifies.
The measure of sleep-apnea progress is what happens to breathing during sleep, alongside symptoms. The number on the scale is only part of that picture.
